SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 10549
FORM 10QSB/A
AMENDMENT TO APPLICATION OR REPORT
Filed pursuant to Section 13 or 15(d) of
THE SECURITIES AND EXCHANGE ACT OF 1934
IGENE BIOTECHNOLOGY, INC.
(Exact name of registrant as specified in charter)
AMENDMENT NO. 2
The undersigned registrant hereby amends the following items, financial
statements, exhibits or other portions of its June 30, 1995 Report on Form
10QSB as set forth in the pages attached hereto:
PART I Financial Information - Addition of Financial Data Statement
pursuant to Article 5.
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the registrant has duly caused this Amendment to be signed on its behalf by
the undersigned, thereunto duly authorized.
IGENE BIOTECHNOLOGY, INC.
Date: October 16, 1995 By: /S/ Stephen F. Hiu
Chief Operating Officer
Principal Financial Officer &
Principal Accounting Officer<PAGE>
<PAGE>
FORM 10QSB/A
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 10549
(Mark One)
[ x ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 1995
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from to .
Commission file number 0-15888 .
IGENE Biotechnology, Inc.
(Exact name of Registrant as specified in its charter)
Maryland 52-1230461
(State or other jurisdiction of incorporation (I.R.S. Employer
or organization) Identification No.)
9110 Red Branch Road, Columbia, Maryland 21045-2020
(Address of principal executive officers) (Zip code)
Registrant's telephone number, including area code: (410) 997-2599
None
(Former name, former address and former fiscal year, if changed since last
report)
Indicate by a check mark whether the Registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the Registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days.
YES X NO
The number of shares outstanding of the Registrant's $.01 par value Common
Stock as of June 30, 1995 is 13,055,738 .
<PAGE>
FORM 10QSB/A
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
IGENE Biotechnology, Inc.
(Registrant)
Date: October 16, 1995
/s/ Stephen F. Hiu
Stephen F. Hiu
President, Treasurer and
Secretary
(On behalf of the Registrant and as
Principal Financial Officer)
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> DEC-31-1995
<PERIOD-START> JAN-01-1995
<PERIOD-END> JUN-30-1995
<CASH> 73,272
<SECURITIES> 0
<RECEIVABLES> 13,831
<ALLOWANCES> 0
<INVENTORY> 1,240
<CURRENT-ASSETS> 91,573
<PP&E> 30,856
<DEPRECIATION> 0
<TOTAL-ASSETS> 133,029
<CURRENT-LIABILITIES> 794,765
<BONDS> 1,500,000
<COMMON> 130,557
472,373
1,875
<OTHER-SE> (2,766,541)
<TOTAL-LIABILITY-AND-EQUITY> 133,029
<SALES> 9,242
<TOTAL-REVENUES> 218,242
<CGS> 7,557
<TOTAL-COSTS> 7,557
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 69,975
<INCOME-PRETAX> (121,719)
<INCOME-TAX> 0
<INCOME-CONTINUING> (121,719)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (121,719)
<EPS-PRIMARY> (0.01)
<EPS-DILUTED> (0.01)
</TABLE>
